Immuron Limited ( (AU:IMC) ) has shared an update.
Immuron Limited has entered into an exclusive distribution agreement with Calmino group AB to launch ProIBS® in Australia and New Zealand for treating symptoms of Irritable Bowel Syndrome (IBS). This collaboration aims to expand Immuron’s digestive health portfolio, leveraging ProIBS®’s proven efficacy and market presence in Europe. The agreement, effective immediately, grants Immuron exclusive distribution rights and is set for a five-year term with an option to extend. This strategic move positions Immuron to strengthen its market presence in the digestive health sector, offering pharmacists a premium product to recommend to consumers.
More about Immuron Limited
Immuron Limited is an Australian biopharmaceutical company that specializes in developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases.
YTD Price Performance: -2.50%
Average Trading Volume: 31,579
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €11.16M
For an in-depth examination of IMC stock, go to TipRanks’ Stock Analysis page.